Literature DB >> 29891111

5-Lipoxygenase: Its involvement in gastrointestinal malignancies.

Neha Merchant1, Lakkakula V K S Bhaskar2, Saimila Momin1, Peela Sujatha3, Aramati B M Reddy4, Ganji Purnachandra Nagaraju5.   

Abstract

Lipoxygenases (LOXs) are dioxygenases that catalyze the peroxidation of linoleic acid (LA) or arachidonic acid (AA), in the presence of molecular oxygen. The existence of inflammatory component in the tumor microenvironment intimately links the LOXs to gastrointestinal (GI) cancer progression. Amongst the six-different human LOX-isoforms, 5-LOX is the most vital enzyme for leukotriene (LT) biosynthesis, which is the main inflammation intermediaries. As recent investigations have shown the association of 5-LOX with tumor metastasis, there has also been significant progress in discovering the function of 5-LOX pathway in GI cancer. Studies on GI cancer cells using the pharmacological drugs targeting 5-LOX pathway have shown antiproliferative and proapoptotic effects. Pharmacogenetic discoveries in other diseases have revealed strong heritable basis for the leukotriene pathway, which helps in exploring the mechanistic source of genetic alteration within the leukotriene pathway and offer insights into GI cancer pathogenesis and future prospects for treatment and prevention. This review recapitulates the current research status of 5-LOX activity in GI malignancies.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  5-Lipoxygenase; GI cancer; Leukotrienes

Mesh:

Substances:

Year:  2018        PMID: 29891111     DOI: 10.1016/j.critrevonc.2018.05.012

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  8 in total

1.  Novel quinolinone-pyrazoline hybrids: synthesis and evaluation of antioxidant and lipoxygenase inhibitory activity.

Authors:  Ioanna Kostopoulou; Antonia Diassakou; Eleni Kavetsou; Eftichia Kritsi; Panagiotis Zoumpoulakis; Eleni Pontiki; Dimitra Hadjipavlou-Litina; Anastasia Detsi
Journal:  Mol Divers       Date:  2020-02-17       Impact factor: 2.943

2.  Zileuton inhibits arachidonate-5-lipoxygenase to exert antitumor effects in preclinical cervical cancer models.

Authors:  Liling Li; Yifang Xiao; Zhengzheng Xu; Shaoshuai Wang
Journal:  Cancer Chemother Pharmacol       Date:  2021-09-03       Impact factor: 3.333

3.  α-Conotoxins Enhance both the In Vivo Suppression of Ehrlich carcinoma Growth and In Vitro Reduction in Cell Viability Elicited by Cyclooxygenase and Lipoxygenase Inhibitors.

Authors:  Alexey V Osipov; Tatiana I Terpinskaya; Tatsiana Yanchanka; Tatjana Balashevich; Maxim N Zhmak; Victor I Tsetlin; Yuri N Utkin
Journal:  Mar Drugs       Date:  2020-04-07       Impact factor: 5.118

4.  Aberrant ALOX5 Activation Correlates with HER2 Status and Mediates Breast Cancer Biological Activities through Multiple Mechanisms.

Authors:  Xiao Zhou; Yi Jiang; Qiuyun Li; Zhen Huang; Huawei Yang; Changyuan Wei
Journal:  Biomed Res Int       Date:  2020-11-10       Impact factor: 3.411

5.  Targeting of the Alox12-12-HETE in Blast Crisis Chronic Myeloid Leukemia Inhibits Leukemia Stem/Progenitor Cell Function.

Authors:  Si Gao; Jialin Hu; Yong Li
Journal:  Cancer Manag Res       Date:  2020-12-03       Impact factor: 3.989

Review 6.  Eicosanoids in Cancer: New Roles in Immunoregulation.

Authors:  Amber M Johnson; Emily K Kleczko; Raphael A Nemenoff
Journal:  Front Pharmacol       Date:  2020-11-18       Impact factor: 5.810

7.  Development and validation of a novel 3-gene prognostic model for pancreatic adenocarcinoma based on ferroptosis-related genes.

Authors:  Jihua Yang; XiaoHong Wei; Fang Hu; Wei Dong; Liao Sun
Journal:  Cancer Cell Int       Date:  2022-01-15       Impact factor: 5.722

8.  ALOX5-5-HETE promotes gastric cancer growth and alleviates chemotherapy toxicity via MEK/ERK activation.

Authors:  Jianjun Tang; Chuang Zhang; Jingjing Lin; Peng Duan; Jian Long; Hongyan Zhu
Journal:  Cancer Med       Date:  2021-06-13       Impact factor: 4.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.